New drug is first to be OK'd for bipolar depression
January 26th 2004Clinicians can now treat patients with bipolar depression using the first drug approved in the U.S. for this indication. The FDA recently approved olanzapine/fluoxetine (Symbyax, Eli Lilly) for the treatment of depressive episodes associated with bipolar disorder. Symbyax is currently available in pharmacies.
New advanced prostate cancer injection bears many restrictions
January 12th 2004Clinicians will soon be able to offer another treatment option to men with prostate cancer who have not responded to hormonal therapy. The FDA recently approved abarelix (Plenaxis, Praecis Pharmaceuticals) for the palliative treatment of men with advanced symptomatic prostate cancer in whom luteinizing hormone releasing hormone (LHRH) agonist therapy is inappropriate and who refuse surgical castration, and have risk of neurological compromise due to metastases; ureteral or bladder outlet obstruction due to local encroachment or metastatic disease; and/or severe bone pain from skeletal metastases persisting on narcotic analgesia. The drug will be available sometime during the first quarter of 2004.
New men's drug offers extended potency
January 12th 2004Clinicians will soon be able to offer men with erectile dysfunction (ED) a new drug that researchers believe has several advantages over currently available therapies. The FDA recently approved tadalafil (Cialis, Eli Lilly) for the treatment of ED. Tadalafil is currently available in pharmacies.
ACCP stays focused on provider status and drug benefit package
December 8th 2003The past year has been one of substantial progress for the American College of Clinical Pharmacy, declared C. Edwin Webb, Pharm.D., MPH, ACCP?s director for government and professional affairs. Provider status for pharmacists remains the association?s priority advocacy issue, and was reaffirmed as such by the Board of Regents, he told attendees at the ACCP annual meeting in Atlanta, Ga., last month.
ACCP stays focused on provider status and drug benefit package
December 8th 2003The past year has been one of substantial progress for the American College of Clinical Pharmacy, declared C. Edwin Webb, Pharm.D., MPH, ACCP?s director for government and professional affairs. Provider status for pharmacists remains the association?s priority advocacy issue, and was reaffirmed as such by the Board of Regents, he told attendees at the ACCP annual meeting in Atlanta, Ga., last month.